Authors : Muhammed Fadhel Pandalingal; Awad El-Hakeem

Volume/Issue : Volume 10 - 2025, Issue 6 - June

Google Scholar : https://tinyurl.com/5b29jncm

DOI : https://doi.org/10.38124/ijisrt/25jun817

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Osteopontin (OPN) is a prominent integrin glycoprotein that plays a considerable role in the progression of chronic hepatic disorders. OPN has more recognized functions, including liver inflammation, fibrosis, and tumours, having once been purely renowned in bone metabolism and cellular adhesion processes. It is convincing that OPN is a good biomarker candidate to assist in the accurate diagnosis of liver diseases, as its increased concentrations coincide with liver damage, fibrosis, and cancer. Chronic liver disease conditions such as alcoholic liver disease and NAFLD depict OPN-driven stellate cells, immune cells, and lipids entering the liver, causing damage and fibrogenesis. In hepatocellular carcinoma, OPN facilitates progression and metastasis through tumour colonization, blood vessel formation, and immune suppression. This supports OPN’s potential as a biomarker to be further investigated in liver damage assessment. This research explains the molecular basis of OPN’s role in liver inflammation and fibrosis, identifies its regulatory pathways, and explores its clinical relevance to liver cancer. The work extends to OPN’s complex functions and utility as a potential therapeutic drug target using in vivo and in vitro models, alongside advanced molecular and histological techniques. Assuming insights into OPN’s regulation and pathological consequences are effective, new therapeutic strategies, including OPN inhibitors or neutralizing antibodies, could be envisaged. These strategies could lead to better control of chronic liver disease and its associated cancers.

Keywords : Osteopontin (OPN), Chronic Liver Disease, Liver Fibrosis, Hepatocellular Carcinoma, Biomarker for Liver Damage.

References :

1. Song, Z., Chen, W., Athavale, D., Ge, X., Désert, R., Das, S., … & Nieto, N. (2021). Osteopontin takes center stage in chronic liver disease. Hepatology, 73(4), 1594-1608. https://doi.org/10.1002/hep.31582
2. Desert, R., Ge, X., Song, Z., Han, H., Lantvit, D., Chen, W., Das, S., Athavale, D., Abraham-Enachescu, I., Blajszczak, C., Chen, Y., Musso, O., Guzman, G., Hoshida, Y., & Nieto, N. (2022). Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis. Hepatology communications, 6(4), 692–709. https://doi.org/10.1002/hep4.1845
3. Tan, Y., Zhao, L., Yang, Y. G., & Liu, W. (2022). The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages. Frontiers in oncology, 12, 953283. https://doi.org/10.3389/fonc.2022.953283
4. Yi Liang, T. (2023). Osteoporosis and Chronic Liver Disease. In Osteoporosis, Osteoarthritis and Rheumatoid Arthritis: An Agonizing Skeletal Triad (pp. 1-16). Bentham Science Publishers.https://doi.org/10.4236/ojgas.2018.812045
5. Vachliotis, I. D., Anastasilakis, A. D., Rafailidis, V., & Polyzos, S. A. (2024). Osteokines in Nonalcoholic Fatty Liver Disease. Current Obesity Reports, 13(4), 703-723.https://doi.org/10.1002/hep.23998
6. Drapkina, O. M., Elkina, A. Y., Sheptulina, A. F., & Kiselev, A. R. (2023). Non-alcoholic fatty liver disease and bone tissue metabolism: current findings and future perspectives. International Journal of Molecular Sciences, 24(9), 8445.
7. Vachliotis, I. D., Anastasilakis, A. D., Rafailidis, V., & Polyzos, S. A. (2024). Osteokines in Nonalcoholic Fatty Liver Disease. Current Obesity Reports, 13(4), 703-723.
8. Bianchi, E., Rontauroli, S., Tavernari, L., Mirabile, M., Pedrazzi, F., Genovese, E., ... & Manfredini, R. (2023). Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. Leukemia, 37(5), 1068-1079.
9. Honda, M., Kimura, C., Uede, T., & Kawa, S. (2020). Neutralizing antibody against osteopontin attenuates non-alcoholic steatohepatitis in mice. Journal of Cell Communication and Signaling, 14(2), 223-232. https://doi.org/10.1007/s12079-020-00554-7
10. Soysouvanh, F., Rousseau, D., Bonnafous, S., Bourinet, M., Strazzulla, A., Patouraux, S., ... & Gual, P. (2023). Osteopontin‐driven T‐cell accumulation and function in adipose tissue and liver promoted insulin resistance and MAFLD. Obesity, 31(10), 2568-2582.
11. Schulien, I., Hockenjos, B., Schmitt‐Graeff, A., Perdekamp, M., Follo, M., Thimme, R., … & Hasselblatt, P. (2019). The transcription factor c-jun/ap-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating osteopontin expression. Cell Death and Differentiation, 26(9), 1688-1699. https://doi.org/10.1038/s41418-018-0239-8